Pharmaceutical Executive, Jan 1, 2008 - Pharmaceutical Executive

ADVERTISEMENT

Pharmaceutical Executive, Jan 1, 2008
Features
Salesforce Survey 2008
By Bob Davenport, Hay Group , Carrie Fisher, Hay Group , Dylan Galaty, Hay Group
Welcome to the new employer's market for reps. The Hay Group's annual survey reports how, as the primary sales force contracts, so too does its pay.
Pharma Forecast: Into the Woods
By Walter Armstrong, Senior Editor
Pharm Exec asks experts to predict what 2008 has up its sleeve for the industry--from the top line to the bottom line, from R&D to M&As, from Congress to the courts.
R&D: Learning to Share
Novartis' Paul Herrling talks about how Big Pharma can learn from nonprofit R&D and collaborate to get an edge on the drug safety problem.
Washington Report
New Year, New Policy Challenges for Pharma
By Jill Wechsler
Pricing, safety, comparative effectiveness, patents, and biosimilars top 2008's policy agenda
From the Editor
Not Enough Science
By Patrick Clinton
A new report says FDA is desperately behind on science. At last, a critique we can actually do something about. But will we?
Tech
Beyond the Foggy Supply Chain
By Dennis Constantinou, Oracle , Arvindh Balakrishnan, Oracle , John Danese, Oracle
More control over warehouse data (from drug company to pharmacist) is key to inventory control
Leadership
The Essential Essner
By Sander Flaum, Flaum Partners
The departure of Wyeth's legendary CEO prompts a reflection on true leadership—and cooking
Column
The Blogosphere: Too Hot for Pharma?
By Fabio Gratton, Ignite Health
Pharma companies would do well to proceed with extreme caution when entering the blogosphere
Lincoln, Digger, and the Rest of the Gang
We asked seven industry experts to talk about today's best (and worst) pharma icons
Creating a Buzz on the Convention Floor
By Stephen Mapes, Impact Unlimited
Utilizing cutting-edge technologies can build an immersive brand experience for your next exhibit
Toolkit
Outsource from the Inside
By Michael Gamble, Yoh Scientific , Chris Hediger, Yoh Scientific
When it comes to clinical teams, the question of whether or not to outsource brings some untraditional answers
Global Report
Oxfam Points Finger
By Sarah Houlton
Pharma defends itself against claims made in charity's report on drug access for the world's poor

ADVERTISEMENT

Click here